New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. Read why some option strategies might be worth considering.

What the science says about lecanemab On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee met to discuss the results from a confirmatory Phase 3 study on ...

Lecanemab, the new Alzheimer’s drug approved by the FDA, explained Lecanemab doesn’t cure Alzheimer’s disease. Patients will still decline — but not as quickly.

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

But lecanemab’s quest for approval has been shadowed by the previous approval of another Alzheimer’s drug to get accelerated approval: aducanemab, sold as Aduhelm. During aducanemab’s ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...